Adding to Targeted Therapy: Current Statistics and Biology - Targeted Therapies in Lung Cancer 2023

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Biomarkers in NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

Resistance on Targeted Therapy: Questions Patients Should Ask-Targeted Therapies in Lung Cancer 2023Подробнее

Stanford Cancer Institute Breakthroughs in Cancer: Luis Diaz, MDПодробнее

Neoadjuvant Treatment for Patients with NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

Adding to Targeted Therapy: Current Statistics and BiologyПодробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

An Expanding Role for Targeted Therapies and Testing in Lung Cancer: Best of Lung 2023Подробнее

2023 Best of Lung: Panel Discussion on Targeted TherapyПодробнее

Biomarker Driven Therapy for NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

Full Event Mainstage 2023 Targeted Therapies in Lung Cancer Patient Forum ON-DEMANDПодробнее

Combination Therapy with Osimertinib for EGFR+ NSCLC - Targeted Therapies in Lung Cancer 2023Подробнее

NTRK+ NSCLC: Treatment Options and Side Effects - Targeted Therapies in Lung Cancer 2023Подробнее

Metastatic EGFR+ NSCLC: Recent Developments - Targeted Therapies in Lung Cancer 2023Подробнее

Treatment Options & Study Data for Patients with ROS1+ NSCLC- Targeted Therapies in Lung Cancer 2023Подробнее

KRAS+ NSCLC: Details and Diagnosis - Targeted Therapies in Lung Cancer 2023Подробнее

The ADAURA Trial: 2023 Updates - Targeted Therapies in Lung Cancer 2023Подробнее

Targeted therapies and genomic profiling for lung cancerПодробнее

Local Therapy for Patients After Frontline Therapy - Targeted Therapies in Lung Cancer 2023Подробнее

Molecularly Targeted Therapies Panel at FACTOR 2023Подробнее